Anti-C5a Vilobelimab Reduces All-cause Mortality in Critically Ill COVID-19 Patients and in Those With Severe ARDS: A Phase 3 Randomized Double-blind, Placebo-controlled Study

Autor:	M. Witzenrath, A.P.J. Vlaar, M. Bauer, D. Annane, L. Heunks, B. Mourvillier, L. Hercilla Vasquez, T. Welte, P. van Paassen, S. de Bruin, E.H.T. Lim, M.C. Brouwer, P.R. Tuinman, J.F. Saraiva, G. Marx, S.M. Lobo, R. Boldo, J. Simon-Campos, A.D. Cornet, A. Grebenyuk, J. Engelbrecht, M. Habel, C. Thielert, J. Dickinson, S. Rückinger, R. Zerbib, D. Neukirchen, K. Pilz, R. Guo, D. van de Beek, N.C. Riedemann, null The PANAMO Study Group
Rok vydání:	2023
Zdroj:	D16. ADVANCING THE SCIENCE OF ARDS AND ACUTE RESPIRATORY FAILURE.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::fcb90370662880a89edb76c104727f1e https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a6237 Zobrazit plný text záznamu